原发性肾小球疾病患者恶性肿瘤风险是否增加?
本综述汇总了肾小球疾病与恶性肿瘤关联的现有证据,估计风险范围为5%至11%,涉及实体瘤及淋巴瘤、白血病等血液系统肿瘤。但既往研究存在未测量混杂、继发性病例纳入、疾病类型错分及检出偏倚等问题,缺乏基于人群的准确癌症风险评估。免疫抑制治疗及蛋白尿、eGFR等疾病活动指标与癌症风险的独立作用尚不明确。
要点
- 肾小球疾病患者恶性肿瘤估计风险为5%至11%,但证据受多种偏倚影响。
- 现有研究缺乏基于人群的准确癌症风险评估,独立危险因素尚不明确。
- 需关注免疫抑制治疗及蛋白尿、eGFR等疾病活动指标与癌症风险的关联。
核心结论
- 肾小球疾病与恶性肿瘤可能存在关联,但现有风险估计受多种偏倚影响,独立危险因素尚不明确。
研究设计与样本
- 综述总结了关于肾小球疾病患者癌症风险的观察性研究和病例系列证据,并探讨既往研究局限及方法学挑战。
主要发现
- 肾小球疾病患者恶性肿瘤估计风险范围为5%至11%,包括实体器官肿瘤及淋巴瘤、白血病等血液系统恶性肿瘤。
- 风险估计受未测量混杂、纳入潜在继发于恶性肿瘤的肾小球疾病病例、肾小球疾病类型错分及检出偏倚影响。
- 长期使用免疫抑制药物及以蛋白尿和eGFR衡量的疾病活动度可能与癌症风险相关,但独立作用 largely unknown。
临床怎么用
- 临床应关注肾小球疾病患者恶性肿瘤风险,考虑常规筛查以实现早期诊断和治疗。
- 需识别可干预的危险因素以降低新发恶性肿瘤风险。
局限性
- 缺乏基于人群的准确评估肾小球疾病患者癌症风险的研究。
- 既往研究存在未测量混杂、继发性病例纳入、疾病类型错分及检出偏倚等方法学局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decade, several observational studies and case series have provided evidence suggesting a connection between glomerular diseases and the development of malignancies, with an estimated risk ranging from 5 to 11%. These malignancies include solid organ tumours as well as haematologic malignancies such as lymphoma and leukaemia. However, these risk estimates are subject to several sources of bias, including unmeasured confounding from inadequate exploration of risk factors, inclusion of glomerular disease cases that were potentially secondary to an underlying malignancy, misclassification of glomerular disease type and ascertainment bias arising from an increased likelihood of physician encounters compared with the general population. Consequently, population-based studies that accurately evaluate the cancer risk in glomerular disease populations are lacking. While it is speculated that long-term use of immunosuppressive medications and glomerular disease activity measured by proteinuria and estimated glomerular filtration rate may be associated with cancer risk in patients with glomerular disease, the independent role of these risk factors remains largely unknown. The presence of these knowledge gaps could lead to a lack of awareness of cancer as a potential chronic complication of glomerular disease, underutilization of routine screening practices in clinical care that allow early diagnosis and treatment of malignancies and underrecognition of modifiable risk factors to decrease the risk of de novo malignancies over time. This review summarizes the current evidence on the risk of cancer in patients with glomerular diseases, explores the limitations of prior studies and discusses methodological challenges and potential solutions for obtaining accurate estimates of cancer risk and identifying modifiable risk factors unique to GN populations.
引用
- Han J, Zhao Y, Canney M, et al. Are patients with primary glomerular disease at increased risk of malignancy? Nephrol Dial Transplant. 2024. PMID: 38070875. doi:10.1093/ndt/gfad261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。